CME 14 Session - EANM'17

Dosimetry/Radiation Protection/Translational Molecular Imaging & Therapy: Alpha Particle Dosimetry, Does High LET Lead to High RBE?

Educational Objectives:
  1. Prerequisites for and experience in the use of alpha particles in translational research
  2. Dosimetry requirements and dose-response relationship for alpha-particles
  3. Imaging, dosimetry and radiation protection in a clinical routine alpha-emitter application
  4. Novel applications for alpha therapies

Alpha emitters are becoming of increasing importance for the application in therapeuticnuclear medicine. For this, translational research which involves in-vitro and animalexperiments with the correspondingly labelled compound is the first step. The respectiveresults of this research need to be then translated into an estimate of the efficacy and safetyof the compound for potential human use.
Dosimetry for alpha particles has to be performed on a small scale due to the short range ofthe alpha particles and a high local absorbed dose for determining the relative biologicaleffectiveness (RBE) of a treatment. For obtaining this quantity the differences in efficacy andtoxicity to the conventional treatment using beta particles need to be assessed.The use of alpha emitters in a clinic environment requires extra measures with respect toimaging, dosimetry and radiation protection. This will be shown for the example of Ra-223therapy; a radiopharmaceutical that has been licensed for treating bone metastases ofprostate cancer.
Other radiopharmaceuticals and isotopes such as Ac-225-labelled PSMA have also beenapplied in patients for treating prostate cancer; results of and experience with this noveltreatment modality will be reported.

Key Words:
Alpha Particles, translational research with alpha emitters, dosimetry, relative biologicaleffectiveness, clinical applications
User action required
If you have the permission to view this publication, please log in.